Retina

Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.

Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.

Walkable communities could aid in reduction of type 2 diabetes.

A study reveals a genetic link between instant coffee consumption and increased risk of dry age-related macular degeneration, urging caution for high-risk individuals.

Incorporating peripheral OCTs into your practice provides valuable insights that may alter your clinical diagnosis.

CLARUS 700, the advanced retinal imaging system, captures 133 degrees in a single image and up to 267 degrees with multiple images.

At the Collaborative Care Symposium, Rachelle Lin, OD, MS, FAAO, highlighted how newer retinal therapies are addressing treatment gaps by offering extended dosing intervals without compromising efficacy—ultimately easing the burden on both patients and providers.

deepeye TPS is designed to close the gap between real-world outcomes and trial data by reducing patient dropout.

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion to cRORA over time.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

In total, 613,690 images used for screening were included in the study.

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared with unimodal models.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

The drug was previously approved for high blood pressure in 1955.

Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda Light Delivery System (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.

Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

Dilsher Dhoot, MD, FASRS, shares his forward-looking perspective on developments in retinal disease management, highlighting both recent breakthroughs and promising innovations on the horizon.

As a retinal expert, Ferrucci discusses some emerging retinal therapies that excite him.

With the acquisition, Topcon Healthcare also assumes RetInSight’s AI algorithms that analyze retinal images to detect and monitor disease.

The company said it will be available on the US market for use in clinics and healthcare institutions.

The optimal triple-carotenoid supports daily eye health with lutein, zeaxanthin, and meso-zeaxanthin, according to the company.